NNVC stock: buy or sell?
May 21st, 2019
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections.
Should I buy NNVC stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with NanoViricides stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is NanoViricides stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for NNVC stock for the last month.
NNVC stock analysis
NanoViricides ended today at $0.25 and stayed stable a tight 0.00%.
NanoViricides shares stayed stable 0.00% to $0.25 today. Since price and SMA200d lines crossed down on March, NNVC fell $-0.14 per share (-35.90%).
NanoViricides eased a godawful -3.85% this week. Late April NNVC plunged a scary -8.00% in just one week. Early April NNVC boosted a dazzling 7.14% in just one week.
Since price and 40-weeks moving average lines crossed down early March, NNVC fell $-0.14 per share (-35.90%). Stocks below the 40w moving average line are usually not recommended for average traders.
NNVC stock price history
NNVC stock went public on October 26th, 2005 with a price of $1.931. Since then, NNVC stock lost a -87.00%, with a yearly average of -6.70%.
1: Adjusted price after possible price splits or reverse-splits.
NNVC stock historical price chart
NNVC stock reached 52-week highs on February at $0.68, and all-time highs 2006-03-21 with a price of 13.13.
NNVC stock price targetPredicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' NNVC stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not found any price prediction for NanoViricides stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareSince last February, when NanoViricides published its last earnings report, it plunged a scary -41.86%. Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn , NanoViricides annual turnover to million dollars from marked in . , its earnings margin (compared to sales) to , that is million.
Quarterly financial resultsReported quarter income marked $-2.23 million with a profit margin of . Profit margin remained steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, NanoViricides sales marked a neutral movement and remained constant a nan%. Looking back to recent quarterly results, NanoViricides posted 7 negative quarters in a row.
NanoViricides ownershipWhen you are planning to invest in a stock, it's worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For NanoViricides, 28.05% of all outstanding shares are owned by its staff.
In case of NanoViricides stock, 5.03% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NNVC stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$19.1 M||$398.1 M||$383.9 M||$77.8 B||$174.1 M|
|Total shares||76.5 M||138.7 M||110.3 M||1,640.0 M||51.1 M|
|Float shares||49.3 M||124.7 M||62.3 M||1,630.0 M||37.8 M|
|- Institutional holdings (%)||5.0%||78.6%||93.6%||75.0%||82.0%|
|- Insider holdings (%)||28.1%||0.1%||1.0%||0.1%||2.5%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Tuesday, May 21st, 2019|
|Day range||$0.25 - $0.26|
|Average true range||$0.02|
|50d mov avg||$0.27|
|100d mov avg||$0.30|
|200d mov avg||$0.32|
NanoViricides performanceTo measure stock performance is always good to compare with competitors or related stocks. For NanoViricides, the comparison is made against Achillion Pharmaceuticals, BioCryst Pharmaceuticals, Bristol-Myers Squibb, Chimerix, Gilead Sciences, GlaxoSmithKline, Merck and NovaBay Pharmaceuticals.